Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Fix the driver behind crashes, sound loss and screen glitches3Clear out junk files and repair common Windows errorsiTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
ALGN can look reasonably valued after its steep five-year fall, but the case depends on more than the lower share price: investors need to believe clear-aligner growth can continue and margins can improve. Align Technology’s Q2 2026 results showed growth in aligners alongside a decline in imaging and CAD/CAM revenue, so the businesses do not currently support a simple “the whole company is recovering” conclusion.
What does Align Technology sell?
Align Technology is a global medical-device and digital-dentistry company. Its two important reported business areas are clear aligners, including Invisalign, and imaging systems/CAD/CAM services, which include iTero intraoral scanners and exocad software. These businesses serve overlapping dental professionals but have different revenue drivers; scanner and software sales should not be treated as aligner revenue.
For investors, that distinction matters because demand for clear-aligner treatment and purchases of professional equipment can move differently. In Q2 2026, aligners grew while imaging and CAD/CAM services declined.
Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →What did Align report in Q2 2026?
Align reported total revenue of $1,056.2 million for the quarter ended June 30, 2026, up 4.3% year over year. The segment results show where that growth came from:
#1 Best Overall
| Business or measure | Q2 2026 result | Year-over-year change |
|---|---|---|
| Clear Aligner revenue | $870.9 million | Up 8.2% |
| Clear-aligner case volume | 691.8 thousand cases | Up 7.4% |
| Imaging Systems and CAD/CAM Services revenue | $185.3 million | Down 10.8% |
All figures in the table are Align Technology’s reported Q2 2026 results, released July 29, 2026. The company attributed the imaging and CAD/CAM decline to softness in capital equipment and a mix shift toward lower-priced scanners and more flexible acquisition models, including leases and rentals. That shift may support scanner adoption, but it also affects the revenue generated per sale or arrangement.
Profit measures are not interchangeable
For Q2 2026, Align reported diluted GAAP EPS of $1.51 and non-GAAP diluted EPS of $2.64. The non-GAAP figure is an adjusted measure, not equivalent to GAAP earnings. Align said both figures were unfavorably affected year over year by about $0.23 due to foreign exchange. Investors comparing valuation multiples or estimating earnings power should keep the accounting basis consistent rather than mix GAAP and adjusted figures.
Cash and repurchases provide context, not a valuation answer
Align reported $1,102.6 million in cash and cash equivalents at June 30, 2026. It also repurchased approximately 0.4 million shares for approximately $67.0 million during Q2 2026. Those figures inform liquidity and capital returns, but do not establish the company’s intrinsic value or show that the stock is underpriced.
Rank #2
- Comes with secure packaging
- Easy to read text
- It can be a gift option
What does the 78% fall tell investors?
A Yahoo Finance article dated September 6, 2026 described ALGN’s five-year share-price decline as about 78.0%. That is a dated secondary-source description of share-price performance, not a measure of the company’s future earnings or fair value. A large decline may reflect lower expectations, weaker operating performance, or a valuation reset; by itself, it cannot distinguish among them or prove that a stock is cheap.
StockAnalysis reported a closing price of $143.74 for ALGN on October 2, 2026. The price is a market snapshot, and it can change quickly. A separate third-party valuation-ratios page showed a current trailing P/E near 25 and a FY 2021 trailing P/E near 67. Those are vendor snapshots whose values depend on the share price, earnings period, and methodology; they are not a like-for-like forecast of future returns.
Yahoo Finance’s September 6, 2026 article also presented a discounted-cash-flow estimate above the then-market price. That is a third-party model output, not an Align forecast or a verified fair value. A discounted-cash-flow result is sensitive to assumptions about future cash generation, growth, margins, and the discount rate; changing those assumptions can materially change the estimate.
What would make the valuation look reasonable?
The central question is whether future earnings and cash flow can justify the current price—not whether the stock has already fallen a lot. A reader can test the thesis by asking whether the operating evidence and assumptions line up:
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
- Aligner demand: Q2 2026 clear-aligner revenue and case volume both grew year over year. The investment case needs that growth to persist rather than treating one quarter as proof of a lasting trend.
- Scanner economics: Lower-priced scanners and leases or rentals may expand access to Align’s digital-dentistry platform, but investors should assess whether the mix shift can support attractive revenue and eventual treatment demand.
- Margin recovery: A valuation based on normalized profitability requires a credible path from current operating conditions to higher margins, not merely an assumed rebound.
- Consistent earnings basis: Any P/E comparison should use a clearly identified earnings measure and period. GAAP and non-GAAP EPS produce different inputs.
- Cash-flow assumptions: A DCF estimate should be judged by its forecast period, growth and margin assumptions, and discount rate. A model output without those assumptions is not enough to establish fair value.
The available figures do not establish one authoritative fair value. That means “reasonable” is conditional: it may fit an investor’s assumptions for sustainable growth and improving profitability, while appearing expensive to someone who expects weaker demand or persistently pressured margins. The share-price decline does not settle that disagreement.
What does management expect, and what could derail it?
In its July 29, 2026 Q2 release, management described expectations for 2026 revenue and clear-aligner volume growth, double-digit year-over-year iTero scanner shipment growth, and a continuing shift toward lower-priced scanners and more flexible acquisition models in the second half of 2026. These are management expectations, not reported outcomes.
The same release said Align expected one-time charges in 2026, including restructuring and accelerated depreciation, and forecast fiscal 2027 operating-margin improvement of approximately 100 basis points year over year. That forecast is one element of a recovery case, but investors should compare it with subsequent reported results and distinguish temporary charges from underlying operating performance.
Operating and market risks
- Clear-aligner demand or case growth could weaken, limiting revenue growth.
- Competition and customer economics could affect treatment volumes, pricing, or adoption.
- Foreign-exchange movements can affect reported results; Align cited an approximately $0.23 year-over-year impact on both Q2 EPS measures.
- Capital-equipment softness and lower-priced scanner or flexible-payment mix could weigh on imaging revenue and margins.
- Margin improvement may fall short of management’s fiscal 2027 expectation, particularly if costs or mix remain unfavorable.
- Scanner adoption and the connection between scanner placements and future treatment demand remain important variables for the two business areas.
Align’s SEC filings provide fuller risk-factor context; the risks above are the ones most directly connected to the current valuation argument.
Free tools Windows power users keep installed
One-click scans. No signup required.
UK VAT matter
Align disclosed that, after an Upper Tribunal determination that clear aligners do not qualify as VAT-exempt dental prostheses for invoices issued on or after September 7, 2026, it estimated a UK liability of approximately $37.5 million including interest and said it intends to appeal. This is the company’s estimate and stated position, not a final determination of the amount ultimately payable or an independent legal conclusion.
Best Value
How to follow the thesis
Investors evaluating ALGN can track a short set of indicators in future company reports:
- Whether clear-aligner revenue and case volumes continue growing.
- Whether Imaging Systems and CAD/CAM Services revenue stabilizes as scanner shipment growth and acquisition-model mix develop.
- Whether reported profitability improves, while keeping GAAP results distinct from non-GAAP adjustments and identified one-time charges.
- Whether management’s revenue, volume, and fiscal 2027 margin expectations are met or revised.
- Whether material foreign-exchange, competitive, demand, or UK VAT developments change the earnings and cash-flow outlook.
Because market prices and valuation ratios move over time, any conclusion should use a dated share price and valuation input period alongside the latest available company results. The Q2 2026 report is the latest earnings information used here.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
